Wei Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wei Zhang has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Bin Fang
State Key Laboratory of Flexible Electronics (LoFE) & Institute of Flexible Electronics (IFE), Xiamen University, Xiamen, 361102, China
1 shared publication- Bo Ma
School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing 211816, China
1 shared publication Bo Peng
State Key Laboratory of Flexible Electronics (LoFE) & Institute of Flexible Electronics (IFE), Northwestern Polytechnical University, Xi'an, 710072, China
1 shared publicationHaixiao Fang
State Key Laboratory of Flexible Electronics (LoFE) & Institute of Flexible Electronics (IFE), Xiamen University, Xiamen, 361102, China
1 shared publicationHang Zhang
State Key Laboratory of Flexible Electronics (LoFE) & Institute of Advanced Materials (IAM), School of Flexible Electronics (Future Technologies), Nanjing Tech University (NanjingTech), Nanjing, 211816, China
1 shared publicationHaoqin Li
State Key Laboratory of Flexible Electronics (LoFE) & Institute of Flexible Electronics (IFE), Northwestern Polytechnical University, Xi'an, 710072, China
1 shared publication
Latest Publications
- Open Access
- 25 March 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Mitochondria in situ releasing corosolic acid enhanced antitumor effects via activating mitophagy in castration-resistant prostate cancer
Corosolic acid (CA) and its derivatives have shown promise as anticancer agents, but their effectiveness against resistant cancer types remains underexplored. Organelle-targeted drug delivery is a promising approach to enhance therapeutic efficacy and reduce side effects. A mitochondria-targeted prodrug, CA-TPP, was synthesized using an esterase-responsive phenolic ester bond, which enables the in situ release of CA within the mitochondria. The therapeutic efficacy of CA-TPP was assessed both in vitro (using DU145 cells) and in vivo. RNA sequencing was employed to investigate the molecular mechanisms, particularly focusing on the PINK1/Parkin-mediated mitophagy pathway. CA-TPP significantly reduced the required treatment dose of CA by 75%, maintaining its anticancer activity. In DU145 cells, CA-TPP induced cell death through the mitochondrial apoptosis pathway. RNA sequencing revealed that CA-TPP activated apoptosis through PINK1/Parkin-mediated mitophagy. Inhibition of mitophagy via PINK1 shRNA alleviated the cytotoxic effects of CA-TPP, confirming the role of mitophagy in its mechanism. Additionally, CA-TPP treatment resulted in elevated ROS production, leading to mitochondrial apoptosis and mitophagy. The CA-TPP prodrug strategy enhances the specificity and anti-tumor effects of corosolic acid, offering a promising approach for targeted cancer therapy. This work opens new possibilities for mitochondria-targeted cancer treatments with reduced drug dosages. This study did not involve clinical trials, and thus trial registration is not applicable. The online version contains supplementary material available at 10.1186/s12967-026-08057-6.
- 25 March 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Open AccessMitochondria in situ releasing corosolic acid enhanced antitumor effects via activating mitophagy in castration-resistant prostate cancer
Corosolic acid (CA) and its derivatives have shown promise as anticancer agents, but their effectiveness against resistant cancer types remains underexplored. Organelle-targeted drug delivery is a promising approach to enhance therapeutic efficacy and reduce side effects. A mitochondria-targeted prodrug, CA-TPP, was synthesized using an esterase-responsive phenolic ester bond, which enables the in situ release of CA within the mitochondria. The therapeutic efficacy of CA-TPP was assessed both in vitro (using DU145 cells) and in vivo. RNA sequencing was employed to investigate the molecular mechanisms, particularly focusing on the PINK1/Parkin-mediated mitophagy pathway. CA-TPP significantly reduced the required treatment dose of CA by 75%, maintaining its anticancer activity. In DU145 cells, CA-TPP induced cell death through the mitochondrial apoptosis pathway. RNA sequencing revealed that CA-TPP activated apoptosis through PINK1/Parkin-mediated mitophagy. Inhibition of mitophagy via PINK1 shRNA alleviated the cytotoxic effects of CA-TPP, confirming the role of mitophagy in its mechanism. Additionally, CA-TPP treatment resulted in elevated ROS production, leading to mitochondrial apoptosis and mitophagy. The CA-TPP prodrug strategy enhances the specificity and anti-tumor effects of corosolic acid, offering a promising approach for targeted cancer therapy. This work opens new possibilities for mitochondria-targeted cancer treatments with reduced drug dosages. This study did not involve clinical trials, and thus trial registration is not applicable. The online version contains supplementary material available at 10.1186/s12967-026-08057-6.